Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Libra Therapeutics develops novel small molecule therapeutics designed to restore cellular balance by improving lysosomal function and autophagy. The company’s lead programs target toxic protein aggregation implicated in ALS, FTD, and other neurodegenerative diseases. Backed by a $29M Series A round led by major biotech investors, Libra’s approach aims to both clear existing toxic proteins and reduce production of new ones. As of mid-2025, all pipeline assets are preclinical or IND-enabling; no clinical results have been published yet.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Libra Healthcare.